I see your points and I disagree: Dr Campbell hi had 10 years to develop the assets and bring them to the clinic and that - and nothing else - would create value for the shareholders ( his job ). He had plenty time to bring DX1 - at least- to human trials or demonstrate that GMP grade for trials can be successfully and repeatedly produced so that perhaps a licensing deal could come forward. Dr Campbell doesn’t even know what the actual problem is with the GMP ‘s run and ‘believes’ that it is a sporadic issue.
Accordingly, Dr Campbell hasn’t done his job properly and now the market will settle for nothing less than a successful run with NO issues attached.
Lastly: judging from the sp it would seem that the selling for tax purposes has been going on for the last six months at least: look at the chart.
- Forums
- ASX - By Stock
- PAB
- Ann: Positive preclinical data for deoxymabs in vasculitis
Ann: Positive preclinical data for deoxymabs in vasculitis, page-51
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
|
|||||
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M |
Open | High | Low | Value | Volume |
0.7¢ | 0.7¢ | 0.7¢ | $620 | 88.51K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
27 | 5809153 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 1618945 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
27 | 5809153 | 0.006 |
16 | 7030776 | 0.005 |
7 | 4425000 | 0.004 |
5 | 2730016 | 0.003 |
2 | 4520000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 1618945 | 3 |
0.008 | 2057547 | 3 |
0.009 | 133332 | 1 |
0.010 | 1592000 | 4 |
0.011 | 1080000 | 2 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |